Medtronic launches Accurian RF ablation system in US

28 February 2019 (Last Updated February 28th, 2019 12:12)

Irish medical devices giant Medtronic has launched the new Accurian radio frequency (RF) ablation system in the US, following 510(k) clearance from the country’s regulatory authority.

Medtronic launches Accurian RF ablation system in US
Medtronic develops a variety of medical devices and technologies across different therapeutic areas. Credit: Medtronic plc.

Irish medical devices giant Medtronic has launched the new Accurian radio frequency (RF) ablation system in the US, following 510(k) clearance from the country’s regulatory authority.

The minimally invasive therapy expands the company’s pain portfolio.

RF ablation involves radio waves-generated current that heats up a small portion of nerve tissue to prevent sending of pain signals and thus reduces pain.

The new device is suitable for standard, pulsed and enhanced procedures. It has internally-cooled probes to create a lesion of various shapes, sizes and volumes.

“The platform combines hardware, quad-core processing and advanced software for power and temperature control to enable consistent and predictable lesion formation.”

Accurian features independent channel management and chip-enhanced probes for easy on-screen detection. It additionally includes smart features such as downloadable procedure reports to facilitate ease of use and efficiency.

The platform combines hardware, quad-core processing and advanced software for power and temperature control to enable consistent and predictable lesion formation.

Medtronic Pain Therapies division senior vice-president and president Marshall Stanton said: “Medtronic has a long-established track record of bringing to market improved options to support clinicians with state-of-the-art technology, like the Accurian RF ablation system, which was designed for consistency and efficiency.

“Medtronic is committed to advancing the treatment of pain as we introduce new options to help patients throughout the care continuum.”

Recently, the US Food and Drug Administration (FDA) has also approved the company’s Resolute Drug-Eluting Stent (DES) platform to treat coronary artery disease patients with de novo chronic total occlusion (CTO).

The approval was based on results from the single-centre, observational PERSPECTIVE Study conducted in 183 CTO patients who demonstrated low repeat revascularisation, cardiac death and minimal stent thrombosis at one year with the Resolute DES.

Furthermore, Medtronic launched Deep Brain Stimulation (DBS) for medically-refractory epilepsy in the US last week.

The therapy is designed to deliver controlled electrical pulses to the anterior nucleus of the thalamus (ANT) in the brain. ANT is part of a network involved in seizures.